Compare Amylx Pharmaceuticals Inc (AMLX) vs Vanguard S&P 500 ETF (VOO) Price & Performance

Amylx Pharmaceuticals IncTrade

Vanguard S&P 500 ETFTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs Vanguard S&P 500 ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while Vanguard S&P 500 ETF trades at $709.65. Which is the better fit depends on your goals.

	AMLX	VOO
Market Cap	$2.53B	—
Sector	Health	Broad Market / Factor
52-Week High	$24.19	$710.71
52-Week Low	$7.82	$580.93
Enterprise Value	$2.28B	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.

Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.

Vanguard S&P 500 ETF

VOO (Vanguard S&P 500 ETF) trades at $710.71, up 0.6% with a bullish technical signal from moving averages. The ETF tracks the S&P 500 index, which recently reclaimed record highs amid strong corporate earnings and AI-driven optimism. Technical indicators show overbought conditions with RSI at 94.45 on the 6-day timeframe, while support levels begin at $708. JPMorgan raised its S&P 500 year-end target to 8,000, citing earnings strength and AI investment payoffs.

The outlook remains positive given robust earnings growth and institutional confidence, though near-term consolidation risks exist from overbought technicals and valuation concerns. Key risks include market breadth weakness and potential September volatility. The ETF's low-cost structure and diversification continue to attract long-term investors seeking S&P 500 exposure.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

AMLX

Amylyx shifts focus to endocrine drug avexitide with strong cash runway into 2028 and key trial results in 2026Seeking Alpha · 4 days agoBullish View details →

VOO

Fidelity's zero-fee fund challenges Vanguard's S&P 500 ETF but offers limited gains for taxable accounts.24/7 Wall Street · 23 hours agoNeutral Vanguard High Dividend Yield ETF lags S&P 500 by $141K over 10 years despite dividends.24/7 Wall Street · 1 day agoBearish Vanguard's S&P 500 ETF (VOO) offers cheaper, more flexible access than the mutual fund VFIAX.24/7 Wall Street · 2 days agoBullish View details →

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

About Vanguard S&P 500 ETF

VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.